Objective: To determine whether divalproex sodium (DVPX) was superior to lithium carbonate (Li+) in the maintenance monotherapy treatment of youths diagnosed with bipolar disorder who had been previously stabilized on combination Li+ and DVPX (Li+/DVPX) pharmacotherapy.
Method: Youths ages 5-17 years with bipolar I or II disorder were initially treated with Li /DVPX. Patients meeting remission criteria for four consecutive weeks were then randomized in a double-blind fashion to treatment with either Li+ or DVPX for up to 76 weeks. Study participation ended if the subject required additional clinical intervention or if the subject did not adhere to study procedures.
Results: Patients were recruited between July 1998 and May 2002. One hundred thirty-nine youths with a mean (SD) age of 10.8 (3.5) years were initially treated with Li+/DVPX for a mean (SD) duration of 10.7 (5.4) weeks. Sixty youths were then randomized to receive monotherapy with Li+ (n = 30) or DVPX (n = 30). The Li+ and DVPX treatment groups did not differ in survival time until emerging symptoms of relapse (p = .55) or survival time until discontinuation for any reason (p = .72).
Conclusions: DVPX was not found to be superior to Li+ as maintenance treatment in youths who stabilized on combination Li+/DVPX pharmacotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.chi.0000155981.83865.ea | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Cancer Lett
January 2015
Department of Pharmacology, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. Electronic address:
Imatinib (IM) represents a breakthrough in the treatment of chronic myeloid leukemia (CML) by inhibiting the activity of Bcr-Abl tyrosine kinase. However, many patients exhibit resistance to IM in the clinic. Recent studies have indicated that sirtuin 1 (SIRT1), a class III histone deacetylase (HDAC), plays an important role in leukemogenesis.
View Article and Find Full Text PDFAdherence to pharmacological treatment for juvenile bipolar disorder.
J Am Acad Child Adolesc Psychiatry
July 2007
Department of Psychiatry, Case Western Reserve University, USA.
Objective: The objective of this study was to describe the prevalence and correlates of adherence to divalproex sodium (DVPX) and lithium carbonate (Li) combination treatment during the initial stabilization treatment phase.
Method: Adherence to Li/DVPX combination therapy was measured by the presence or absence of minimum serum concentrations of DVPX (50 microg/mL) or Li (0.6 mmol/L).
Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization.
J Am Acad Child Adolesc Psychiatry
February 2006
From the Departments of Psychiatry (R.L.F., N.K.M., R.S., R.E.W., C.A.D., J.R.C.), Psychology (E.A.Y.), and Pediatrics (R.L.F., M.D.R.), Case Western Reserve University, University Hospitals (R.L.F., N.K.M., R.S., M.D.R., J.R.C.), Cleveland, OH; and Strong Memorial Hospital (B.L.G.), University of Rochester Medical Center, Rochester, NY.
Objective: It has been reported that bipolar disorder may become less responsive to previously effective treatment with each symptomatic relapse. The primary goal of this study was to assess the rate of re-stabilization after the resumption of lithium (Li) plus divalproex (DVPX) following relapse on either agent as monotherapy.
Method: This is a prospective, 8-week, open-label outpatient Li/DVPX combination therapy trial.
Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder.
J Am Acad Child Adolesc Psychiatry
May 2005
Department of Psychiatry, Case Western Reserve University, USA.
Objective: To determine whether divalproex sodium (DVPX) was superior to lithium carbonate (Li+) in the maintenance monotherapy treatment of youths diagnosed with bipolar disorder who had been previously stabilized on combination Li+ and DVPX (Li+/DVPX) pharmacotherapy.
Method: Youths ages 5-17 years with bipolar I or II disorder were initially treated with Li /DVPX. Patients meeting remission criteria for four consecutive weeks were then randomized in a double-blind fashion to treatment with either Li+ or DVPX for up to 76 weeks.
Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania.
J Affect Disord
October 2004
Pediatric Bipolar Research Program, Department of Psychiatry, University of Illinois at Chicago (UIC), Chicago, IL 60612, USA.
Objective: This prospective 6-month open trial examined the safety and efficacy of two combination therapies for manic or mixed episodes of pediatric bipolar disorder: (1) divalproex sodium plus risperidone (DVPX+Risp), or (2) lithium plus risperidone (Li+Risp).
Methods: Thirty-seven (37) subjects aged 5 and 18 (age=12.1+/-3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!